SCYNEXIS, Inc. (SCYX) News
Filter SCYX News Items
SCYX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SCYX News From Around the Web
Below are the latest news stories about SCYNEXIS INC that investors may wish to consider to help them evaluate SCYX as an investment opportunity.
Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years agoWe're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits... |
11 Cheapest Stocks With Biggest UpsideIn this piece, we will take a look at the 11 cheapest stocks with the biggest upside. If you want to skip our introduction to stock valuation and recent market news, then take a look at 5 Cheapest Stocks With Biggest Upside. Identifying the right stocks to invest in is a science that involves evaluating […] |
SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateIND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advanceRemediation strategies following the voluntary recall of BREXAFEMME® and the MARIO study clinical hold are being evaluatedWith cash, cash equivalents and investments of $105.2 million as of September 30, 2023, SCYNEXIS projects a cash runway of more than two years JERSEY CITY, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biote |
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens. The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve Universit |
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, GreeceJERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM) |
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substanceBREXAFEMME Carton BREXAFEMME Blister Pack JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME® tablets. During a review of manufacturing equipment and cleaning activities at a supplier, SCYNEXIS was ma |
Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?Verve Therapeutics (VERV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination riskScynexis said on Monday it would voluntarily recall its antifungal pill, which it has licensed to GSK, due to risk of cross-contamination with a potential allergy-inducing compound, sending the drugmaker's shares tumbling over 30%. The drugmaker said it became aware substances used to make drugs that contain beta-lactam are manufactured using equipment also used to make its treatment, called Brexafemme. The U.S. Food and Drug Administration's guidelines require companies to segregate the manufacturing of beta-lactam compounds from other drugs because they may trigger hypersensitivity or an allergic reaction in some people. |
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?SCYNEXIS' (NASDAQ:SCYX) stock is up by a considerable 18% over the past three months. As most would know, fundamentals... |